SOUTH SAN FRANCISCO, CA--(Marketwire - April 24, 2009) - Theravance, Inc. (NASDAQ: THRX)announced today that the U.S. Food and Drug Administration (FDA) acceptedas complete for review Theravance's response to the February 2009 CompleteResponse letter, which outlined requirements for approval of telavancin...
Trending Articles
More Pages to Explore .....